During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.

The rise in number of fertility clinics to support the market growth during the forecast period.

Significant rise in number of fertility clinics, coupled with the decline in the fertility rate across the globe. Along with this growing focus of players and government towards the launching and acquiring new fertility centers across the globe is likely to contribute towards the growth of the segment. The expansion of fertility clinics equipped with advanced technology is anticipated to increase the accessibility of infertility treatment devices among infertile couples.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=43497112

Asia Pacific likely to emerge as the fastest-growing infertility treatment market, globally

Geographically, the emerging Asian countries, such as ChinaIndiaJapan and Singapore, are offering high-growth opportunities for market players. The Asia Pacific point of care market is projected to grow at the highest CAGR of 9.1% from 2021 to 2026. Expansion of healthcare infrastructure and increase in disposable personal income, rising medical tourism in Asian countries, increasing healthcare expenditure, and growing awareness among people about infertility are supporting the growth of the infertility treatment market in the region. 

The fertility rate worldwide is declining steadily owing to various factors, such as the growing trend of late marriages and increasing age-related infertility. Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. 

For More Info, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112 

Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally.

The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.

The infertility treatment market include major Tier I and II suppliers of infertility treatment equipment, media & consumables are The Cooper Companies Inc. (US), Cook Group (US), Vitrolife (Sweden), Thermo Fisher Scientific, Inc. (US), Esco Micro Pte. Ltd. (Singapore), Genea Biomedx (Australia), IVFtech ApS (Denmark), FUJIFILM Irvine Scientific (US), The Baker Company, Inc. (US), Kitazato Corporation (Japan), Rocket Medical plc (UK), IHMedical A/S (Denmark), Hamilton Thorne Ltd. (US), ZEISS Group (Germany), MedGyn Products, Inc. (US), DxNow, Inc. (US), Nidacon International AB (Sweden), Gynotec B.V. (Netherlands), SAR Healthline Pvt. Ltd. (India), and InVitroCare Inc. (US). These suppliers have their manufacturing facilities spread across regions such as North AmericaEuropeAsia Pacific.